Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cellectar Biosciences, Inc. - Common Stock (NQ: CLRB ) 0.2535 -0.0222 (-8.05%) Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Cellectar Biosciences, Inc. - Common Stock < Previous 1 2 3 Next > 12 Health Care Stocks Moving In Wednesday's Pre-Market Session December 11, 2024 Via Benzinga Crude Oil Jumps 2%; Macy's Lowers Earnings Forecast December 11, 2024 Via Benzinga Exposures Fossil Fuels Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options December 11, 2024 Due to FDA communications, Cellectar Biosciences will explore options for development of its cancer drug. Focus on isotopes for solid tumors. Via Benzinga Exposures Product Safety Nasdaq Surges Over 1%; US Inflation Rises In-Line With Expectations December 11, 2024 Via Benzinga Topics Economy Exposures Interest Rates Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket December 11, 2024 Via Benzinga Earnings Preview For Cellectar Biosciences March 26, 2024 Via Benzinga Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring December 10, 2024 From Cellectar Biosciences, Inc. Via GlobeNewswire Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update November 18, 2024 From Cellectar Biosciences, Inc. Via GlobeNewswire Earnings Scheduled For November 18, 2024 November 18, 2024 Via Benzinga Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225 November 14, 2024 From Cellectar Biosciences, Inc. Via GlobeNewswire Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer November 12, 2024 Cellectar broadens global manufacturing network in preparation for potential commercialization of Iopofosine I 131 in 2025 From Cellectar Biosciences, Inc. Via GlobeNewswire Gold Moves Higher; Coca-Cola Increases FY24 Forecast July 23, 2024 Via Benzinga Crude Oil Down 2%; GE Aerospace Earnings Top Views July 23, 2024 Via Benzinga Exposures Fossil Fuels Cancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer Study July 23, 2024 Cellectar Biosciences stock drops 19.2% following the release of CLOVER WaM study results. The pivotal study for iopofosine I 131 in relapsed/refractory Waldenstrom's macroglobulinemia showed an 80%... Via Benzinga Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session July 23, 2024 Via Benzinga CLRB Stock Earnings: Cellectar Biosciences Misses EPS for Q1 2024 May 14, 2024 CLRB stock results show that Cellectar Biosciences missed analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Hedgeye Warns That Reddit (RDDT) Stock Will Fall 50% March 27, 2024 Reddit stock is a hot topic among traders on Wednesday after one analyst warns that RDDT could give up 50% of its gains. Via InvestorPlace Why Is Gamida Cell (GMDA) Stock Down 82% Today? March 27, 2024 Gamida Cell stock is falling on Wednesday with heavy trading of GMDA shares after the company announced plans to go private. Via InvestorPlace CLRB Stock Earnings: Cellectar Biosciences Beats EPS for Q4 2023 March 27, 2024 CLRB stock results show that Cellectar Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023. Via InvestorPlace Earnings Scheduled For March 27, 2024 March 27, 2024 Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million. Via Benzinga Cellectar Biosciences Is An 'Attractive Acquisition Target' According To This Analyst - Here's Why March 04, 2024 Cellectar Biosciences reports positive Phase 1 trial results for iopofosine I 131 in head and neck squamous cell carcinoma, achieving 64% complete remission and 73% overall response rate. Roth Capital... Via Benzinga Why Is Cancer-Focused Cellectar Biosciences Stock Trading Higher Today? January 08, 2024 Cellectar Biosciences Inc (NASDAQ: CLRB) announced data from its CLOVER WaM pivotal study, evaluating iopofosine I 131, a targeted radiotherapy candidate for the treatment of relapsed/refractory... Via Benzinga Wells Fargo Is Warming Up to Enphase Energy (ENPH) Stock January 08, 2024 Enphase Energy stock is rising higher on Monday as investors react to a new upgrade and increased price target for ENPH from Wells Fargo. Via InvestorPlace Why Is Spirit AeroSystems (SPR) Stock Down 14% Today? January 08, 2024 Spirit AeroSystems stock is falling hard on Monday as investors in SPR react to one of the company's flights experiencing a mid-air blowout. Via InvestorPlace Why Is LumiraDx (LMDX) Stock Down 13% Today? January 08, 2024 LumiraDx stock is falling hard on Monday as investors in LMDX prepare for the company's shares to be delisted on Tuesday! Via InvestorPlace Why Is Cellectar Biosciences (CLRB) Stock Up 16% Today? January 08, 2024 Cellectar Biosciences stock is up on Monday as investors celebrate positive study results with heavy trading of CLRB stock this morning. Via InvestorPlace Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday January 08, 2024 It's time to start the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Monday morning! Via InvestorPlace 12 Health Care Stocks Moving In Friday's Intraday Session September 22, 2023 Via Benzinga 12 Health Care Stocks Moving In Wednesday's Pre-Market Session September 06, 2023 Via Benzinga Crude Oil Rises 1%; Verb Technology Shares Spike Higher September 05, 2023 U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones falling 100 points on Tuesday. The Dow traded down 0.31% to 34,728.66 while the NASDAQ rose 0.11% to 14,047.61. The S&P... Via Benzinga Topics Stocks Exposures Fossil Fuels US Equities < Previous 1 2 3 Next > Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
